| INTRODUCTION
The FibroTest has been validated as a biomarker for the diagnosis of the stages of fibrosis in NAFLD 1, 2 with results similar to those in CHC, [3] [4] [5] CHB, 5, 6 and ALD, 7, 8 although no study has validated its prognostic value for liver-related death. This could be due to the natural history of NAFLD, with lower incidence of liver-related death and higher non-liver-related causes of mortality in comparison with the viral or alcoholic liver diseases. In a study of FibroTest in 2312 patients with type 2 diabetes or dyslipidemias, we found a significant prognostic value of FibroTest, for the overall survival. 9 In type 2 diabetes, FibroTest predicted cardiovascular events and improved the Framingham-risk score. For the prediction of liver-related death the number of events at 10 years was too small (n = 7) for any conclusion. Therefore, the primary aim was to assess the prognostic value on liver-related death, and we focused on subjects of the FibroFrance program followed since 1997 in the department of Hepatology for chronic liver diseases in Pitié-Salpêtrière hospital), and compared the performances of FibroTest in NAFLD to those of CHC, in order to have a sufficient sample size.
The second aim was to assess the prognostic values of apolipoprotein-A1 (ApoA1) and haptoglobin, two hepatoprotective proteins 10-13 also associated with lower risk of non-liver mortality, including cancer and cardiovascular related deaths. The third aim was to assess the prognostic performance of two new quantitative tests, assessing the severity of NASH (NashTest-2) 14 and of steatosis (SteatoTest-2). 14 
| PATIENTS AND METHODS

| Study design
The design was an analysis of fresh serum specimen recorded in a non-interventional prospective cohort. Patients followed by the Hepatology department were from the "Groupe Hospitalier Pitié Sal- CT01927133). STROBE statements were followed (Table S1 ). The protocol was approved by the institutional review board, regulatory agency and performed in accordance with principles of Good Clinical
Practice. All patients provided written informed consent before entry. All authors had access to the study data and reviewed and approved the final manuscript.
Patients with a FibroTest performed before 2013, without previous liver transplantation, and without acute liver disease, were selected ( Figure 1 ). Follow-up and treatments were scheduled according to the updated international guidelines. 15, 16 In patients with baseline cirrhosis ultrasonography (US) examination was performed every 6 months, and AFP was recommended every 6 months. 
| Non-invasive liver biomarkers
| Statistical methods
Survival analyses (events defined as death) were based on univariate All statistical analyses were performed using NCSS-12.0 and R softwares, including timeROC library. . Besides the causes of liver disease there was no significant differences between the pre-included and included subset characteristics (Table 1 ).
| RESULTS
| Characteristics of included subjects
Between patients with NAFLD patients and those of the comparator group with CHC there were two main significant differences Table 1 ).
| Survivals
The median (range) follow-up was 6.0 years (0. There was a dramatic difference in the survivals among NAFLD patients 50 years of age or older ( Figure S1A ), mainly due to the number of non-liver-related cancers ( Figure S1B) , and of the cardiovascular-related deaths ( Figure S1C ), despite less liver-related deaths in the CHC patients ( Figure S1D ).
Among patients younger than 50 years of age there was no difference between NAFLD vs CHC overall survivals ( Figure S2A ), including no difference between non-liver-related cancers deaths ( Figure S2B) , with an early difference in cardiovascular-related deaths ( Figure S2C ), but compensated by less liver-related deaths (Figure S2D ). All the five quantitative components of FibroTest were associated (AUROCs) with liver-related deaths both in NAFLD as in CHC (Table S2) . (Table S3 ).
| FibroTest prognostic value for survival without non-liver-related deaths
Deaths from any causes occurred in NAFLD 240 patients vs 449 in the CHC group. The AUROC for the prediction of overall-survival in patients with NAFLD was low, 0.507 (0.443-0.571) and much lower than its AUROC in patients with CHC, 0.738 (0.708-0.768; P < 0.001),
as expected according to the higher prevalence of liver-related deaths in CHC (6.6%, n = 226) vs NAFLD (3.5%, n = 38) ( Table 1) Other-related deaths occurred in 81 NAFLD vs120 CHC patients.
FibroTest had no significant predictive value for survival without other-related deaths in patients with NAFLD 0.398 (0.307-0.489) and was significant in CHC, 0.580 (0.524-0.638; P = 0.002).
| Number of events and cumulative probability of death according to Fibrotest cutoffs
Most of the 10-yr mortality in cirrhotic patients was related to liverrelated deaths both in NAFLD and CHC. In non-cirrhotic patients, whatever the stages of fibrosis presumed by FibroTest, there was a lower mortality related to liver deaths in NAFLD as compared to CHC (Table S4) . These patients with NAFLD had rare alcohol consumption but under the standard definition of consumption at risk (mean daily alcohol consumption ≥30 g for men and ≥20 g for women). 
| ApoA1 and haptoglobin prognostic values for survival without liver-related deaths
Low ApoA1 was associated in patients with NAFLD, with cardiovascular-related deaths (P = 0.009) (Table 2A) , and with all causes of deaths (P < 0.001) ( Table 2) , independently of age, gender, and fibrosis severity estimated by A2M. In CHC ApoA1 was associated with non-liver-related cancer death and all causes of death (Table 3) .
High haptoglobin was associated in patients with NAFLD, with cardiovascular-related deaths (P = 0.03) (Table 2B) , and with all causes of deaths (P = 0.003) (Table 2F) , independently of age, gender and fibrosis severity estimated by A2M. In CHC high haptoglobin was associated with cardiovascular-related deaths, and with non-liver-related cancer death (Table 2D ). In CHC, and contrarily to NAFLD low haptoglobin was associated with all causes of death, as expected by the high prevalence of liver-related deaths in CHC and the low level of haptoglobin in cirrhosis (Table 3) .
| Prognostic performance of NASH or Steatosis biomarkers
A total of 680 patients with NAFLD had FibroTest together with new NashTest-2 and SteatoTest-2 (Table S5 ). For liver-related deaths, in univariate analysis, despite the limited number of events (n = 17) the two biomarkers of NAFLD had significant predictive value, but only the significance of NashTest-2 persisted when adjusted on FibroTest (Table S5B ). The other causes of deaths were not associated with elevated NashTest-2 or SteatoTest-2. For all causes of deaths, there was even a negative association with NashTest, significant both in uni and multivariate analyses (Table S5C ,D).
| Prediction of deaths among patients with cirrhosis
Staging of NAFLD into seven categories using FibroTest predicted decreasing 5-year survival without related-deaths in F4.3 vs F4.2 and F4.1 as validated previously in CHC and CHB ( Figure S5 ).
| Sensitivity analyses
Exclusion of NAFLD patients with alcohol consumption missing (n = 250), or with rare alcohol consumption but under the standard definition of consumption at risk (daily alcohol consumption ≥30 g for men and ≥20 g for women) (n = 37) (Table S6) 
| DISCUSSION
In this study, we validated the performance of FibroTest for the prognostic of patients with NAFLD, both for the survival without liver-related deaths the primary aim, and for the overall survival. We also confirm that FibroTest has prognostic value for cardiovascularrelated deaths in patients with NAFLD, mainly due to the prognostic value of ApoA1.
This long-term follow-up of a prospective cohort has several strengths and limitations.
| Strengths
The first strength was the sample size and the long-term follow-up, which permitted to analyse a total of 240 deaths in the NAFLD group including 38 liver-related deaths, much more than in our previous study in two different cohorts which analysed 172 deaths For the first time, as presumed by quantitative blood tests, we were able to assess if the severity of NASH and steatosis at baseline were predictive of survivals, independently of baseline fibrosis severity. Indeed, in the subset population with all these tests, despite the limited number of events (n = 17) NashTest-2 and SteatoTest-2 had significant predictive value. As expected, only the significance of NashTest-2 persisted when adjusted on FibroTest.
We confirmed our previous results in type 2-diabetes, that FibroTest predicted cardiovascular events, and improved the Framinghamrisk score. 9 For the first time we observed that FibroTest was also predictive of cardiovascular-related deaths, both in NAFLD patients with and without diabetes and also among CHC patients.
There is evidence that low ApoA1 and low haptoglobin are two blood biomarkers of mortality risk, besides their performance for the diagnosis of cirrhosis. 10, 11 They both mediate hepatoprotection. In healthy volunteers testing acetaminophen, these proteins were differentially expressed before acetaminophen intake in subjects with an increase in transaminases vs those without. 19 Similarly, in patients with drug-induced liver injury, higher serum levels of these proteins were predictive of transaminase recovery. 12 We also recently 
| Limitations
First, we have not performed an external validation. However, the prognostic value of FibroTest in NAFLD was already validated for overall survival and the risk of cardiovascular events in diabetic patients of the FibroFrance project, 9 and its diagnostic performance has been extensively validated in NAFLD patients. Even if this study had the longest follow-up and the higher number of events in comparison with the other published prognostic study in NAFLD, the number of events was still low. We found the same prevalence of primary liver cancer associated deaths than in the other prognostic studies, but more cases are needed to validate the prognostic value of biomarkers for liver cancer occurring in noncirrhotic NAFLD or for the prediction of cholangiocarcinoma.
We did not analyse the predictive value of evolving risk factors during follow-up, such as alcohol intake or diabetes. We also did not analyse the predictive value of steatosis, being overweight, tobacco, coffee, chocolate or cannabis consumption, physical exercise or longterm drug use, all factors that could be associated not only with fibrosis but also with cardiovascular deaths. rior to FibroTest in face to face study, and using intention to diagnose analysis, for chronic viral hepatitis and alcoholic liver disease. 5, 8, 16 To assess liver fibrosis in NAFLD, EASL guidelines recommends the use of either NAFLD-Fibrosis-score, FIB-4 score, Fibrometer, ELF as well as Fibrotest. To assess the liver-related prognosis in NAFLD there is so far no guidelines.
In Conclusion, the FibroTest has a high predictive value for survival without liver disease in patients with NAFLD, as already observed in chronic viral hepatitis and alcoholic liver disease.
